I wholeheartedly concur! The current trajectory appears exceedingly promising over the three-month period you referenced. I eagerly anticipate the outcomes of the Phase 2 trials in Pitt Hopkins syndrome and Angelman syndrome, given the significant potential attributed to NNZ-2591, which surpasses that of Rett Syndrome by more than fivefold. I perceive a confluence of favorable factors. Furthermore, the noteworthy achievement of a $157 million profit after tax for 2023 adds to the company's compelling narrative.
I wholeheartedly concur! The current trajectory appears...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.64 |
Change
-0.380(2.00%) |
Mkt cap ! $2.427B | |||
| Open | High | Low | Value | Volume |
| $19.20 | $19.28 | $18.55 | $3.775M | 200.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 216 | $18.64 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.66 | 440 | 9 |
View Market Depth
| Last trade - 11.25am 05/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$18.79 |
Change
-0.380 ( 1.50 %) |
||||
| Open | High | Low | Volume | ||
| $19.12 | $19.26 | $18.55 | 49702 | ||
| Last updated 11.46am 05/06/2024 ? | |||||
| NEU (ASX) Chart |